ES2100893T3 - Procedimiento de preparacion de una vacuna o de un agente toxico. - Google Patents

Procedimiento de preparacion de una vacuna o de un agente toxico.

Info

Publication number
ES2100893T3
ES2100893T3 ES90914003T ES90914003T ES2100893T3 ES 2100893 T3 ES2100893 T3 ES 2100893T3 ES 90914003 T ES90914003 T ES 90914003T ES 90914003 T ES90914003 T ES 90914003T ES 2100893 T3 ES2100893 T3 ES 2100893T3
Authority
ES
Spain
Prior art keywords
vaccine
preparation procedure
toxic agent
pathogenic
colonized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90914003T
Other languages
English (en)
Inventor
Philip Alfred Brunell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cedars-Sinai Medical Center
Original Assignee
Cedars-Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars-Sinai Medical Center filed Critical Cedars-Sinai Medical Center
Application granted granted Critical
Publication of ES2100893T3 publication Critical patent/ES2100893T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Semiconductor Lasers (AREA)
  • Spark Plugs (AREA)

Abstract

UN METODO DE VACUNA O PREPARACION TOXOIDE E INMUNIZACION CONTRA UNA ENFERMEDAD PATOGENICA. UN AREA DEL CUERPO SE COLONIZA CON MICROORGANISMOS INDIGENAS QUE HAN SIDO TRANSFORMADOS MEDIANTE TECNOLOGIA DE ADN RECOMBINANTE PARA EXPRESAR ANTIGENOS PATOGENICOS. LOS MICROORGANISMOS TRANSFORMANTES COLONIZADOS REPLICARAN Y OBTENDRAN UNA INMUNORESPUESTA AL ANTIGENO PATOGENICO, PROTEGIENDO DE ESTA MANERA AL INDIVIDUO DE UNA EXPOSICION SUBSECUENTE AL PATOGENO INTACTO.
ES90914003T 1989-11-01 1990-08-30 Procedimiento de preparacion de una vacuna o de un agente toxico. Expired - Lifetime ES2100893T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/430,491 US5149532A (en) 1989-11-01 1989-11-01 Method of vaccine or toxoid preparation and immunization by colonization with recombinant microorganisms

Publications (1)

Publication Number Publication Date
ES2100893T3 true ES2100893T3 (es) 1997-07-01

Family

ID=23707776

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90914003T Expired - Lifetime ES2100893T3 (es) 1989-11-01 1990-08-30 Procedimiento de preparacion de una vacuna o de un agente toxico.

Country Status (8)

Country Link
US (1) US5149532A (es)
EP (1) EP0498804B1 (es)
JP (1) JPH05501401A (es)
AT (1) ATE149569T1 (es)
CA (1) CA2072657A1 (es)
DE (1) DE69030099T2 (es)
ES (1) ES2100893T3 (es)
WO (1) WO1991006654A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737521B1 (en) * 1990-05-11 2004-05-18 The Rockefeller University Delivery and expression of a hybrid surface protein on the surface of gram positive bacteria
GB2261372A (en) * 1991-11-15 1993-05-19 Gregor Reid Lactobacillus and skim milk compositions for prevention of urogenital infection
DK0652758T3 (da) * 1992-06-18 2000-05-08 Harvard College Diferitoxin-vacciner
US6455673B1 (en) 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
GB9521568D0 (en) * 1995-10-20 1995-12-20 Lynxvale Ltd Delivery of biologically active polypeptides
AU774535B2 (en) * 1995-10-20 2004-07-01 Actogenix Nv Delivery of biologically active polypeptides
US7780961B2 (en) * 2001-05-03 2010-08-24 Actogenix N.V. Self-containing Lactococcus strain
DE60319822T2 (de) * 2002-06-19 2009-06-04 Actogenix Nv Verfahren und mittel zur erhöhung der darmabsorption
AU2003298291A1 (en) * 2002-11-15 2004-06-15 Universiteit Gent Self-containing lactobacillus strain
DK2119450T3 (da) 2005-11-29 2013-05-06 Actogenix Nv Induktion af mucosal tolerance over for pankreatisk ø-beta-celle-autoantigener
BRPI0807857A2 (pt) 2007-01-25 2014-05-27 Actogenix Nv Tratamento de doença imune por meio de distribuição através da mucosa de antígenos.
SMT201800368T1 (it) 2012-05-16 2018-09-13 Immune Design Corp Vaccini per l'infezione da virus-2 herpes simplex

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4888170A (en) * 1981-10-22 1989-12-19 Research Corporation Vaccines obtained from antigenic gene products of recombinant genes
CA1338705C (en) * 1981-10-22 1996-11-12 Roy Curtiss Iii Vaccines obtained from antigenic gene products of recombinant genes
PT77014B (en) * 1982-07-20 1986-01-24 Molecular Genetics Inc Production of herpes simplex viral proteins
AU589114B2 (en) * 1984-02-01 1989-10-05 Enterovax Limited Genetically engineered bacteria useful as a vaccine
NL8503316A (nl) * 1985-11-29 1987-06-16 Stichting Nl I Zuivelonderzoek Werkwijze voor het bereiden van proteinen met behulp van gastheer-organismen, in het bijzonder melkzuurbacterien, welke recombinant dna-plasmiden met een hoge replicon-aktiviteit en een hoge promotor-aktiviteit voor het betreffende proteine-coderende gen bevatten, de van dergelijke recombinant dna-plasmiden voorziene gastheerorganismen, de recombinant dna-plasmiden zelve, de replicon-aktiviteit en promotor-aktiviteit coderende dna-fragmenten, alsmede de verkregen proteinen.
EP0319690A1 (en) * 1987-11-24 1989-06-14 Nisshin Flour Milling Co., Ltd. Method of introducing foreign DNA into certain bacteria

Also Published As

Publication number Publication date
EP0498804B1 (en) 1997-03-05
WO1991006654A1 (en) 1991-05-16
ATE149569T1 (de) 1997-03-15
US5149532A (en) 1992-09-22
DE69030099T2 (de) 1997-07-31
JPH05501401A (ja) 1993-03-18
EP0498804A4 (en) 1992-12-09
CA2072657A1 (en) 1991-05-02
EP0498804A1 (en) 1992-08-19
DE69030099D1 (de) 1997-04-10

Similar Documents

Publication Publication Date Title
ES2154738T3 (es) Composicion que comprende un virus recombinante que expresa un antigeno y un virus recombinante que expresa una molecula inmunoestimuladora.
ES2065303T5 (es) Procedimiento de diagnosis y vacuna especifica.
ATE295895T1 (de) Genetischer impfstoff gegen den immunschwäche virus
BR0107972A (pt) Uso de uma proteìna ou polinucleotìdeo tat do hiv, nef do hiv, ou tat do hiv ligado(a) a uma proteìna ou polinucleotìdeo nef do hiv (nef-tat), e de uma proteìna ou polinucleotìdeo gp120 do hiv, método para imunizar um ser humano contra o hiv, e, composição de vacina para o uso humano
ES2098029T3 (es) Vacunas de hepatitis que contienen monofosforil lipido a 3-o-desacilado.
ES2152421T3 (es) Vacunas de conjugados polisacarido neumococcico-neumolisina recombinante para la inmunizacion contra las infecciones neumococcicas.
FR2814958B1 (fr) Composition vaccinale
ES2140076T3 (es) Vacunas que contienen una saponina y un esterol.
BR9106748A (pt) Vacina de hyopneumomiae micoplasma inativado e metodo de seu uso
PE11298A1 (es) Vacunas
CY1108147T1 (el) Εμβολιο κατα των σεξουαλικως μεταδιδομενων νοσων
DE68927348D1 (de) Künstlicher impfstoff gegen aids-virus
ES2054696T3 (es) Agente viral de la hepatitis nanb, antigen y reactivo inmunologico.
ES2160601T3 (es) Vacunas de conjugado de polisacaridos de estreptococos del grupo b tipo ii y tipo v-proteina.
BR0113155A (pt) Métodos para produção de uma vacina para hepatite b e de um antìgeno de superfìcie para hepatite b e para tratamento e/ou profilaxia de infeções pelo vìrus da hepatite b, composição de vacina, uso de um antìgeno de superfìcie para hepatite b, antìgeno imunogênico de hepatite b e vacina
ES2097759T3 (es) Anticuerpos especificos para el dominio de fijacion de cd4 de hiv.
PE72699A1 (es) Antigeno del rotavirus, vacuna y agente diagnostico para infeccion por rotavirus y un metodo para producir el antigeno
EP0716613A4 (en) TREATING A GASTRODUODENAL DISEASE CAUSED BY -i (HELICOBAKTER PYLORI)
ES2089923T3 (es) Composicion de vacuna subunitaria recombinante viva y procedimiento de preparacion.
DE69030099D1 (de) Verfahren zur herstellung von impfstoffen oder toxoiden
NL300183I1 (nl) Acellulair vaccin.
DE69720065D1 (de) Therapeutische anwendungen von antigenen oder epitopen assoziert mit unvollständiger zellulärer peptidprozesierung , z.b.: exprimiert in rma-s zellen transfiziert mit b7-1 gen
ES2106032T3 (es) Vacuna para inmunizar gatos contra el desprendimiento de oocistos de toxoplasma.
PT636030E (pt) Vacina de bacterina-toxoide de pasteurella haemolytica tipo a-1
FR2270891A2 (en) Vaccines by glutaraldehyde detoxification - especially multivalent vaccines e.g. against tetanus and diphtheria

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 498804

Country of ref document: ES